
BofA starts Biohaven at purchase, cites “fast-follower” approach (NYSE:BHVN)
peterschreiber.media BofA began protection of Biohaven (NYSE:BHVN) with a purchase ranking, citing its drug improvement applications for temper and autoimmune problems. The funding…


